FDA Approves Extended-Release Injection for Opioid Use Disorder

TUESDAY, May 30, 2023 -- The U.S. Food and Drug Administration has approved Brixadi (buprenorphine) extended-release injection to treat moderate-to-severe opioid use disorder.
Brixadi is approved for both weekly (8 mg, 16 mg, 24 mg, 32 mg) and...